Drug Trial Radar · NCT07421284
A Study to Evaluate the Safety, Efficacy of SYH2053 in Chinese Participants With Non-familial Hypercholesterolemia and Mixed Hyperlipidemia on a Background of Lipid-lowering Therapy
Last checked: Nov 19, 2026Latest source record: Feb 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
900
Planned (sponsor's estimate)
Start
Mar 31, 2026
Primary completion
Dec 31, 2027
Study completion Jan 31, 2028
Sponsor
- Lead sponsor
- CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Feb 19, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare the effectiveness, safety of SYH2053 in participants with primary hypercholesterolemia (non-familial) or mixed dyslipidemia on a background of lipid-lowering therapy. This trial plans to enroll 900 Participants.
Conditions
- Non-familial Hypercholesterolemia and Mixed Hyperlipidemia
Interventions
SYH2053/placebo injectionDrug
Participants receive SYH2053/placebo injection by subcutaneous administration.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage change in LDL-C relative to baselineTime frame: Day 330
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Affiliation: Peking University Third Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.